SCHEMBL278338

SCHEMBL278338

C=C(C)C(=O)N(O)CCN(O)C(=O)C(=C)C

nearest known ligand 0.36

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 1/20 0.36
ALDH1A1 P00352 1/20 0.32
TSHR P16473 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11345617 0.87 MAPT (0.32) TDP1
SCHEMBL1250604 0.87 CA12 (0.34) TDP1ALDH1A1TSHR
SCHEMBL2221793 0.81
SCHEMBL6238242 0.77 TDP1 (0.35) TDP1TSHR
Hydrochloric Acid SCHEMBL7805288 0.77 ACHE (0.41) TSHR
SCHEMBL327516 0.75 ALDH1A1 (0.35) TDP1ALDH1A1
SCHEMBL6682180 0.75 TSHR (0.39) TDP1ALDH1A1TSHR
SCHEMBL11347329 0.73
SCHEMBL526286 0.73 TDP1 (0.42) TDP1ALDH1A1
SCHEMBL9814628 0.72 TDP1 (0.36) TDP1ALDH1A1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3200840-B1 LOW-WATER CONTENT ACRYLATE-ACRYLAMIDE COPOLYMERS FOR OPHTHALMIC DEVICES ALCON INC (CH) 2021-11-17 EP claimed
EP-3200839-B1 HYDROPHOBIC ACRYLATE-ACRYLAMIDE COPOLYMERS FOR OPHTHALMIC DEVICES NOVARTIS AG (CH) 2019-09-04 EP claimed
EP-3223870-B1 WET-PACK INTRAOCULAR LENS MATERIALS WITH HIGH REFRACTIVE INDEX NOVARTIS AG (CH) 2018-09-26 EP claimed
US-10064977-B2 Wet-pack intraocular lens materials with high refractive index NOVARTIS AG (CH) 2018-09-04 US claimed
US-9921341-B2 Low-water content acrylate-acrylamide copolymers for ophthalmic devices NOVARTIS AG (CH) 2018-03-20 US claimed
US-9864102-B2 Hydrophobic acrylate-acrylamide copolymers for ophthalmic devices NOVARTIS AG (CH) 2018-01-09 US claimed
EP-3223870-A1 WET-PACK INTRAOCULAR LENS MATERIALS WITH HIGH REFRACTIVE INDEX Novartis AG (CH) 2017-10-04 EP claimed
WO-2016133656-A1 WET-PACK INTRAOCULAR LENS MATERIALS WITH HIGH REFRACTIVE INDEX NOVARTIS AG (CH) 2016-08-25 WO claimed
US-20160235886-A1 WET-PACK INTRAOCULAR LENS MATERIALS WITH HIGH REFRACTIVE INDEX ALCON INC. (CH) 2016-08-18 US claimed
US-20160170092-A1 HYDROPHOBIC ACRYLATE-ACRYLAMIDE COPOLYMERS FOR OPHTHALMIC DEVICES ALCON INC. (CH) 2016-06-16 US claimed
US-20160170093-A1 LOW-WATER CONTENT ACRYLATE-ACRYLAMIDE COPOLYMERS FOR OPHTHALMIC DEVICES ALCON INC. (CH) 2016-06-16 US claimed
EP-3200840-B1 LOW-WATER CONTENT ACRYLATE-ACRYLAMIDE COPOLYMERS FOR OPHTHALMIC DEVICES ALCON INC (CH) 2021-11-17 EP disclosed
EP-3200839-B1 HYDROPHOBIC ACRYLATE-ACRYLAMIDE COPOLYMERS FOR OPHTHALMIC DEVICES NOVARTIS AG (CH) 2019-09-04 EP disclosed
EP-3223870-B1 WET-PACK INTRAOCULAR LENS MATERIALS WITH HIGH REFRACTIVE INDEX NOVARTIS AG (CH) 2018-09-26 EP disclosed
US-10064977-B2 Wet-pack intraocular lens materials with high refractive index NOVARTIS AG (CH) 2018-09-04 US disclosed
US-8133512-B2 Drug delivery systems based on catonic siloxanyl macromonomers BAUSCH & LOMB INCORPORATED (US) 2012-03-13 US disclosed
US-20090274745-A1 Drug delivery systems based on catonic siloxanyl macromonomers BAUSCH & LOMB INCORPORATED (US) 2009-11-05 US disclosed
US-20090274744-A1 Drug delivery system based on cationic siloxanyl macromonomers BAUSCH & LOMB INCORPORATED (US) 2009-11-05 US disclosed
US-7579021-B2 Drug delivery systems based on degradable cationic siloxanyl macromonomers BAUSCH & LOMB INCORPORATED (US) 2009-08-25 US disclosed
US-20080075780-A1 Drug delivery systems based on degradible cationic siloxanyl macromonomers SANTARUS, INC. 2008-03-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090274744-A1 Drug delivery system based on cationic siloxanyl macromonomers MSR1, LPXN, SRRM2 TDP1 3506/4885ALDH1A1 3479/4885TSHR 2302/4885
US-20090274745-A1 Drug delivery systems based on catonic siloxanyl macromonomers MMP13, LPXN, SLC13A2 TDP1 3872/4885ALDH1A1 1770/4885TSHR 2498/4885
US-20080075780-A1 Drug delivery systems based on degradible cationic siloxanyl macromonomers MSR1, LPXN, SRRM2 TDP1 3411/4885ALDH1A1 3230/4885TSHR 1721/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.